According to recent data, death rate is more than 20% for 75 years old hospitalized patients and older. In case of aggravation, according to the latest observations, if they are refused for mechanical ventilation in intensive care, their death rate could reach 60% even for patients without comorbidity. Apart from an increase in oxygen therapy, no specific treatment is currently proposed. The control of the inflammatory component seems to be a key element to be able to influence the patients' health evolution. Polyvalent intravenous immunoglobilins have immunomodulatory and anti-inflammatory properties with a favorable safety profile for these elderly patients and several clinical cases lead to positive impact in the caring for Covid patients. This study objective is evaluation of the efficacy of polyvalent IVIg in combination with the standard management of patients aged 75 and over with SARSCov2 infection with acute respiratory failure (saturation ≤ 95%) requiring oxygen therapy\> 5 L / min (i.e. patients considered as moderate to severe ARDS according to the Berlin definition, Pa02 / Fi02≤200) and disqualified from a care in the ICU.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
Centre Hospitalier de Versailles
Le Chesnay, France
RECRUITINGMortality
Time frame: Day 14
Total number of days of full hospitalization
Time frame: 3 and 6 months
Duration of oxygen therapy
Time frame: 3 and 6 months
Ferritin level in the blood
Time frame: 3 and 6 months
CRP level in the blood
Time frame: 3 and 6 months
LDH level in the blood
Time frame: 3 and 6 months
Lymphocyte level in the blood
Time frame: 3 and 6 months
PNN level in the blood
Time frame: 3 and 6 months
platelet level in the blood
Time frame: 3 and 6 months
WHO performance index
Time frame: 3 and 6 months
WHOQOL-OLD questionnaire
Time frame: 3 and 6 months
Lung function by pulmonary computed tomography
Time frame: 3 and 6 months
Lung function by EFR
Time frame: 3 and 6 months
Mortality
Time frame: 3 and 6 months
Readmission Rates
Time frame: 3 and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.